LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Начало・Списък с акции・Exelixis Inc

Exelixis Inc

Затворен

Сектор Здравеопазване

25.14 -1.37

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

25.1

Максимум

25.64

Ключови измерители
By Trading Economics
Приходи	189M 226M
Продажби	212M 637M
P/E Средно за сектора	34.57 103.001
EPS	0.84
Марж на печалбата	35.486
Служители	1,310
EBITDA	215M 284M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+11.65 upside

Дивиденти
By Dow Jones
Следващи печалби	30.10.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-191M 7.9B
Предишно отваряне	26.51
Предишно затваряне	25.14

Настроения в новините

By Acuity

50%

114 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

N/A / 25.7 Подкрепа & съпротива

Exelixis Inc Графика

Свързани новини

6.09.2024 г., 22:41 ч. UTC

Пазарно говорене

KinderCare and StandardAero File for IPOs -- Market Talk

6.09.2024 г., 21:18 ч. UTC

Топ новини

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6.09.2024 г., 21:05 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6.09.2024 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.09.2024 г., 20:39 ч. UTC

Печалби

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6.09.2024 г., 20:35 ч. UTC

Топ новини

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6.09.2024 г., 20:34 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6.09.2024 г., 20:11 ч. UTC

Топ новини

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6.09.2024 г., 19:51 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6.09.2024 г., 19:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Hold Gains -- Market Talk

6.09.2024 г., 19:14 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6.09.2024 г., 19:01 ч. UTC

Пазарно говорене

Gold Slips on Prevailing Uncertainty -- Market Talk

6.09.2024 г., 18:27 ч. UTC

Топ новини

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6.09.2024 г., 18:25 ч. UTC

Пазарно говорене

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6.09.2024 г., 18:15 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6.09.2024 г., 18:12 ч. UTC

Топ новини

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6.09.2024 г., 17:44 ч. UTC

Пазарно говорене

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6.09.2024 г., 17:30 ч. UTC

Пазарно говорене

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6.09.2024 г., 17:30 ч. UTC

Топ новини

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6.09.2024 г., 17:27 ч. UTC

Топ новини

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6.09.2024 г., 17:00 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.09.2024 г., 17:00 ч. UTC

Пазарно говорене

Mexican Inflation Seen Easing in August -- Market Talk

6.09.2024 г., 16:36 ч. UTC

Пазарно говорене

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6.09.2024 г., 16:35 ч. UTC

Печалби

Горещи акции

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6.09.2024 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Печалби

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Exelixis Inc Прогноза

Ценова цел

By TipRanks

11.65% нагоре

12-месечна прогноза

Среден 28.08 USD 11.65%

Висок 33 USD

Нисък 25 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Exelixis Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Exelixis Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 25.7Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

114 / 365 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно Exelixis Inc

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.